Although our short-term ex vivo explant experiment revealed that CU-PC01 tumours are not initially sensitive to AKT inhibition, future work to explore the long-term efficacy of PI3K/AKT-directed therapy in vivo is warranted to inform AR-negative mCRPC treatment decisions in the clinic. The gene discussed is AKT1; the disease is neoplasm.